Metagen Therapeutics Secures 300 Million Yen to Accelerate Ulcerative Colitis Drug Development and Fecal Microbiota Transplantation Supply Chain

Overview of Funding

In September 2026, Metagen Therapeutics, Inc. announced the completion of a 300 million yen funding round through a second close of its Series B extension round, with GLIN Impact Capital—an impact and ESG investment fund—serving as the underwriter. This latest injection brings the total raised in this round to 490 million yen, pushing the company's cumulative funding to 7.14 billion yen.

About Metagen Therapeutics

Spun out from Juntendo University, Keio University, and Institute of Science Tokyo (formerly Tokyo Medical and Dental University), Metagen Therapeutics operates under the corporate purpose of "continuously fulfilling patients' hopes through microbiome science." The company develops medical services and drug discovery businesses leveraging fecal microbiota transplantation (FMT). Operating out of the "Tsuruoka Stool Donation Room" in Tsuruoka City, Yamagata Prefecture, the company has established an integrated supply chain spanning everything from donor recruitment to investigational drug manufacturing.

Purpose of Funding and Future Outlook

The newly acquired funds will be allocated toward advancing the clinical development of its ulcerative colitis therapeutic candidate "MGT-006," conducting clinical research targeting gastrointestinal cancers and Parkinson's disease, and optimizing the stool donation supply chain. Furthermore, with the support of GLIN Impact Capital, Metagen Therapeutics aims to establish a framework for measuring and managing the social impact of FMT, striving to create a new medical industry that balances robust business growth with expanded social impact.